The structurally defined sea anemone peptide toxins ShK and BgK potently block the intermediate conductance, Ca 2؉ -activated potassium channel IKCa1, a well recognized therapeutic target present in erythrocytes, human T-lymphocytes, and the colon. The well characterized voltage-gated Kv1.3 channel in human T-lymphocytes is also blocked by both peptides, although ShK has a ϳ1,000-fold greater affinity for Kv1.3 than IKCa1. To gain insight into the architecture of the toxin receptor in IKCa1, we used alanine-scanning in combination with mutant cycle analyses to map the ShK-IKCa1 interface, and compared it with the ShK-Kv1.3 interaction surface. ShK uses the same five core residues, all clustered around the critical Lys 22 , to interact with IKCa1 and Kv1.3, although it relies on a larger number of contacts to stabilize its weaker interactions with IKCa1 than with Kv1.3. The toxin binds to IKCa1 in a region corresponding to the external vestibule of Kv1.3, and the turret and outer pore of the structurally defined bacterial potassium channel, KcsA. Based on the NMR structure of ShK, we deduce the toxin receptor in IKCa1 to have x-y dimensions of ϳ22 Å, a diameter of ϳ31 Å, and a depth of ϳ8 Å; we estimate that the ion selectivity lies ϳ13 Å below the outer lip of the toxin receptor. These dimensions are in good agreement with those of the KcsA channel determined from its crystal structure, and the inferred structure of Kv1.3 based on mapping with scorpion toxins. Thus, these distantly related channels exhibit architectural similarities in the outer pore region. This information could facilitate development of specific and potent modulators of the therapeutically important IKCa1 channel.
(AA603035, AA65228), ovary (AA424836, AA443903, AA425636), testis (AI081834), and platelets (10) . IKCa1 is activated by intracellular calcium via a calmodulin-dependent mechanism (13) , and its amino acid sequence exhibits ϳ40% identity with the sub-family of small conductance calcium-activated potassium channels (1) (2) (3) (4) (5) (6) . Clotrimazole, a potent but nonselective inhibitor of this channel, is currently being evaluated in the therapy of sickle cell disease and secretory diarrheas. Although initial results have been encouraging (5, (14) (15) (16) , there is clearly a need for more specific inhibitors of IKCa1, and architectural information on this channel may facilitate drug development.
The use of peptide toxins to obtain insight into the topology of the external vestibule of potassium channels has a long and successful history. Structurally defined peptides from scorpion venom and sea anemone have been used as molecular yardsticks to gauge the dimensions and shape of the external vestibules of the voltage-gated Shaker and Kv1.3 channels (17) (18) (19) (20) (21) (22) (23) . The deduced dimensions are in good agreement with the recently published structure of the outer pore region of the bacterial potassium channel, KcsA, based on crystallographic data (24, 25) . Therefore, the use of peptide toxins as mapping tools, set in the context of the known KcsA crystal structure, can facilitate the architectural mapping of the outer pore regions of pharmacologically important mammalian potassium channels in the absence of direct structural data for these channels.
Although IKCa1 is only distantly related to the Shaker and Kv1.3 voltage-gated channels, it is potently blocked by some of the same scorpion and sea anemone peptides that inhibit these channels. It might therefore be feasible to use the peptidemapping approach to gain insight into the dimensions and shape of the toxin receptor on IKCa1 and to compare this topology with the external vestibules of Kv1. 3 and KcsA. For this purpose, we have used the structurally defined 35-amino acid peptide toxin, ShK, 1 from the sea anemone Stichodactyla helianthus. We used the alanine scanning method, coupled with mutant cycle analyses, to map the interactive surface between ShK and IKCa1 and compared this with the ShK: Kv1.3 interface. Our studies indicate that ShK binds to IKCa1 in an external vestibule that is architecturally similar to that of Shaker, Kv1.3, and KcsA, although ShK uses a significantly wider surface to interact with IKCa1 compared with its interaction with Kv1. 3 . Such structural differences might be exploited to guide the design of novel peptides that specifically target IKCa1.
MATERIALS AND METHODS
Peptide Synthesis-Fmoc-amino acid derivatives were obtained from Bachem A.G. (CH-4416 Bubendorf, Switzerland). Solid-phase assembly was initiated with an Fmoc-Cys(Trt)-2-chlorotrityl resin to minimize potential racemization of the C-terminal Cys residue. Automated stepwise assembly was carried out entirely on an ABI-431A peptide synthesizer (Applied Biosystems, Foster City, CA). The ShK analogues were solubilized, oxidized, and purified by reverse phase-high pressure liquid chromatography using the method described previously (23, 26) , and high pressure liquid chromatography-pure fractions were pooled and lyophilized. The structure and purity of the peptides were confirmed by reverse phase-high pressure liquid chromatography, amino acid analysis, and electrospray ionization-mass spectroscopy analysis. Samples were weighed and adjusted to account for peptide content before bioassay.
Reagents-A cell line stably expressing mKv1.3 (27) was maintained in Dulbecco's modified Eagle's medium containing 10% fetal calf serum and 1 mg/ml G418 (Life Technologies, Inc.). The Kv1. (His 3 Val) mutant has been described previously (20) . The human IKCa1 expression construct has previously been described (3, 4, 13) (20, 28) . The cRNA along with a marker dye was injected into rat basophilic leukemia cells as described previously (13, 28) . After 2-6 h, dye-containing cells with specific currents could be characterized using the patch-clamp method. Cell lines stably expressing Kv1.3-wild type (27) were trypsinized and plated onto glass coverslips at least 3 h before measurement. All cells were measured in the whole-cell configuration and bathed in mammalian Ringer solution with 0.1% bovine serum albumin (Sigma) containing (in mM): 160 NaCl, 4.5 KCl, 2 CaCl 2 , 1 MgCl 2 , 10 HEPES, adjusted to pH 7.4 with NaOH, with an osmolarity of 290 -320 mOsm. In the K ϩ -Ringer solution, NaCl was replaced with KCl. A simple syringe-driven perfusion system was used to exchange the bath solutions in the recording chamber. The internal pipette solution for the Kv1. 3 ) is a measure of the difference in free energy between the interaction of an ShK analogue with the channel, compared with that of wild-type ShK (26) .
Double Mutant Cycle Analysis-This method evaluates the strength of the interaction between any pair of channel and toxin residues. For each mutant cycle, we measured the potency (K d ) of ShK and its analogues on IKCa1 and its mutants. The change in coupling energy, ⌬⌬G, for a given pair of ShK-IKCa1 residues and their mutants was calculated using the formula ⌬⌬G ϭ kT ln ⍀, as described earlier (20, 23) . Based on the studies of Schreiber and Fersht (29) and Hidalgo and MacKinnon (19) , ⌬⌬G values Ն 0.5 kcal mol Ϫ1 indicate that a particular pair of ShK and IKCa1 residues are likely to lie within 5 Å of each other. (30, 31) . These peptides share 31% sequence identity (Fig. 1A) . Both contain six conserved cysteines that form three disulfide bonds, a feature common to many channel-blocking peptide inhibitors from scorpion venom as well as many defensins (32) . However, the structures of ShK and BgK are significantly different from that of the scorpion toxins and defensins (23, 33, 34 (Fig. 1B, top panel) , indicating that this peptide has an exquisite ability to discriminate between the two T lymphocyte K ϩ channels. Determining the IKCa1 Channel-binding Surface of ShK-To elucidate the molecular basis for the ability of ShK to discriminate between IKCa1 and Kv1.3, we used alanine-scanning mutagenesis to identify ShK residues essential for binding to both these channels. A series of monosubstituted peptide analogues, in which each residue is substituted with alanine, was tested for their ability to block the IKCa1 and Kv1.3 channels. The only exception is His 19 , which was replaced by a lysine. Structurally critical ShK residues that were not substituted included the six half-cysteine residues, as well as Asp . Using this approach, we determined ⌬F for each alanine substitution. The ShK residues most critical for IKCa1 binding, with ⌬F values greater than or equal to 2.5, are shown in red in Fig. 2A (shown in blue, ⌬F ϭ 0.5-0.75), are only moderately important for binding, whereas Ala substitutions at the remaining ShK positions (shown in white, ⌬F Ͻ 0.5) have minimal effects ( Fig. 2A) . Fig. 3 (left) shows the positions of the ShK residues (bottom and side view) that contribute to its interaction with IKCa1, color coordinated with the histograms in Fig. 2A . All the highly critical residues (⌬F Ն 2.5) cluster together on one surface of the ShK peptide (red), and Met 21 (orange) lies immediately adjacent. Residues with moderate influence (yellow and blue) form the margins of the ShK:IKCa1-binding surface. In general, nonessential residues cluster together on the opposite surface of the peptide (Fig. 3, left) . Thus, the surface of ShK that binds IKCa1 extends in its greatest distance from Arg 1 on one side to Phe 15 on the other (Fig. 3, left, Fig. 2A , and see Fig. 1B, bottom panel) . Alanine substitutions at ShK positions 11, 21, and 27 (⌬F ϭ 0.75-1.5) and positions 1, 6, 7, 15, and 26 (⌬F Ͻ0.75) are also substantially less disruptive on Kv1.3 compared with IKCa1 (Fig. 2B) . The only exception is ShK-Arg 29 , which seems to be slightly more important for binding to Kv1.3 than for IKCa1 (⌬F ϭ 0.88 and 0.56, respectively). Our results thus suggest that ShK uses a larger number of residues to stabilize its interaction with IKCa1 than with Kv1.3, although it uses the same core domain of five clustered residues for binding to both channels.
RESULTS

The
ShK-Lys 22 protrudes into the Kv1.3 pore and lies in close proximity to Tyr 400 and Asp 402 in the selectivity filter, and is critical for the interaction of the toxin with this channel (23) . To determine the contribution of Lys 22 to the interaction of the toxin with IKCa1, we compared the affinity of IKCa1 and Kv1.3 for four ShK-Lys 22 analogues (Fig. 2B) ; we also examined the effect of these analogues on the Kv1.3-His 404 3 Val 404 mutant, and these data are presented in a subsequent section. In two analogues, the positively charged lysine is replaced with the shorter, positively charged amino acids, ornithine (Orn) and diaminopropionic acid (Dap), whereas the other two analogues have the neutral residues norleucine (Nle) and alanine (Ala) at position 22. These residues differ in their side chain lengths (Dap, 2.5 Å; Ala, 2 Å; Orn, 5.0 Å; Nle, 5.0 Å; lysine, 6.3Å). Our results show that Ala 22 and Nle 22 substitutions significantly decrease the affinity of the toxin for both channels ( Fig. 2B ; ⌬F Ն 2.1), suggesting that the presence of these bulky neutral residues in the pore of either channel destabilizes the toxinchannel interaction. In contrast, the positively charged ShKDap 22 and ShK-Orn 22 exhibit different affinities for the two channels. The Dap 22 substitution severely abrogates the affinity of the toxin for IKCa1 (⌬F Ͼ2.5), but does not significantly alter the affinity of ShK for Kv1.3 (Fig. 1B, bottom left and Fig.  2B ). The longer ShK-Orn 22 substitution also significantly disrupts the affinity of the toxin for IKCa1 (⌬F ϭ 1.7), although to a lesser extent than Dap 22 , possibly because it is better anchored in the channel pore, whereas this analogue blocks Kv1.3 with potency equivalent to wild-type ShK (Fig. 2B) . Fig. 3 highlights the residues that ShK uses to interact with IKCa1 (left) compared with those for Kv1.3 (right). The residues are color-coordinated with the histogram in Fig. 2, A . Alanine substitutions at any of these five critical positions in the binding core domain severely disrupt the ShK-channel interaction in both channels (⌬F Ͼ 1.5, Fig. 3, red and Kv1.3 (Fig. 3) . Nevertheless, the affinity of the toxin for Kv1.3 is significantly greater than for IKCa1 (Fig. 1B) , suggesting that the picomolar affinity of ShK for Kv1.3 is dependent on a few very tight toxin-channel contacts, whereas its ϳ1,000-fold lower nanomolar affinity for IKCa1 is because of a greater number of weaker interactions.
Interactions of ShK with Residues in the External
Vestibule of IKCa1-Peptides from scorpion and snake venom, as well as from sea anemone, bind to residues in the external vestibule of the ion conduction pathway of eukaryotic voltage-gated potassium channels and occlude their pores (17) (18) (19) (20) (21) (22) (23) 34) . This vestibule corresponds to the outer pore and turret region in the structurally defined bacterial K ϩ channel, KcsA (24) , and mutations in the turret region of KcsA greatly enhance the ability of this channel to bind peptide inhibitors (25) . We therefore undertook a series of mutational analyses to define the interactions of ShK with residues in the external vestibule of IKCa1.
Charge-reversal Mutation at IKCa1-Asp 239 Dramatically Reduces Sensitivity to ShK-We first aligned the turret and pore regions of KcsA, Kv1.3, and IKCa1 (Fig. 4A) . All three channels are remarkably similar in the pore region with absolute conservation of the GYGD motif (Fig. 4A) (20, 23) . A charge-reversal mutation involving Asp 386 in Kv1.3 (Asp 3 Lys) substantially reduces the channel sensitivity to ShK (⌬F ϭ 1.9), kaliotoxin (⌬F Ͼ 2.5), and charybdotoxin (⌬F Ͼ 2.5) (20, 23) . The converse charge-reversal mutation at the homologous position in KcsA (Arg 64 3 Asp 64 ) enhances this channels sensitivity for agitoxin-2 (25) . We therefore replaced IKCa1 Asp 239 with the positively charged Lys, and examined the sensitivity of the mutant channel to ShK. The IKCa1-Lys 239 mutant was expressed in rat basophilic leukemia cells, and representative currents, elicited by 1 M calcium in the pipette solution, are shown in Fig. 4B . The mutant channel is ϳ18-fold less sensitive to ShK (K d ϭ 548 Ϯ 37 nM) than wild-type IKCa1, suggesting that the Asp 3 Lys charge-reversal mutation at position 239 in IKCa1 has the same consequences on ShK binding as the identical mutation at the homologous position in Kv1.3 (23) . The change in free energy for this channel mutant (⌬F ϭ 1.7 kcal mol Ϫ1 ) is equivalent to severe Ala substitutions (⌬F Ͼ1.5 kcal mol Ϫ1 ) in ShK (compare with Fig. 2A) Fig. 2 (for color code, see Fig. 2A ). The models were generated with the RasMol program.
that this channel residue is a critical contact point at the toxin-channel interface.
IKCa1 on the channel-binding surface, whereas ShK-Lys 9 is on the nonbinding surface of ShK (Fig. 3) . Fig. 4C (Fig. 5, left) , as has been reported for Kv1.3 (23) rather than with Asp 239 in opposite IKCa1 subunits.
ShK-Lys 22 Protrudes into the IKCa1 Pore and This Interaction Is Dependent on the K
ϩ Ion Concentration in the PoreBecause Lys 22 is located at the lowest and central point in the channel-binding surface of ShK (Fig. 3) , there is a good likelihood that it lies close to or within the pore of IKCa1, as has been reported for Kv1.3 (23) . To test this idea, we examined whether the terminal amine of ShK-Lys 22 lies close to a potassium-binding site in the ion selectively filter. Earlier studies have shown that Lys 22 in ShK, and the homologous Lys 27 in the scorpion toxins, agitoxin-2 and kaliotoxin, lie in close proximity to a potassium-binding site in the ion selectivity filter of the Kv1.3 and Shaker channels (21, 22) . Occupancy of this site by a K ϩ ion appears to destabilize the interaction of the native toxins with these channels via electrostatic repulsion of Lys 27 , because it has little effect on toxin analogues containing neutral substitutions at position 27 (21, 22) . Similarly, potassium ions were shown to inhibit the interaction between Lys 27 (but not Asn 27 ) in charybdotoxin and residues in the pore of the large conductance, calcium-activated K ϩ channel, BK (35) . We have used a similar approach to determine whether ShK-Lys 22 lies in the vicinity of a potassium-binding site in the IKCa1 pore. We compared the effect of changing the external K ϩ concentration from 4.5 to 164.5 mM on the affinity of the IKCa1 channel for ShK-Lys 22 and ShK-Ala 22 . Consistent with earlier reports, increasing external [K ϩ ] also reduces the potency of ShK-Lys 22 on the IKCa1 channel (7.7-fold), whereas block by ShK-Ala 22 is minimally affected (1.6-fold). We assessed the strength of this interaction using mutant cycle analysis (Fig.  4D) . The ⌬⌬G value for this cycle (0.91 kcal mol Ϫ1 ) indicates that ShK-Lys 22 lies within 5 Å of a K ϩ -binding site located in the IKCa1 pore, as has been reported for Kv1.3 (23) .
Since ShK-Lys 22 protrudes into the pores of both IKCa1 and Kv1.3, why is the IKCa1 pore more sensitive to ShK-Lys 22 substitutions than the Kv1.3 pore, especially those involving shorter positive charged residues (Orn 22 and Dap 22 )? A comparison of the sequences of the outer pore regions of the two channels suggests an explanation (Fig. 4A) (23) . Fourth, the critical ShK-Lys 22 lies close to a potassium-binding site in the selectivity filter of the Kv1.3 pore (23), and mutant cycle analyses suggests the same is true for IKCa1 (Fig. 4D) . Last, replacement of the critical ShK-Lys 22 with bulky neutral residues (Nle and Ala) substantially reduces the affinity of the toxin for both channels, possibly because such residues are not tolerated in the channel pore. These results indicate that ShK binds to IKCa1 in a region corresponding to the external vestibules of Kv1.3 and uses a comparable docking geometry. Such a docking configuration would place Arg 1 and Phe 15 , the two residues at opposite margins of the IKCa1-binding surface (Fig. 3A) , in close proximity to channel residues in opposite subunits in the IKCa1 tetramer (Fig. 5) .
Knowing the NMR structure of ShK (33) and its approximate docking configuration in IKCa1, we used this peptide as a structural template to estimate the dimensions of the toxin receptor in the external vestibule of IKCa1. We have obtained two independent estimates of the diameter of the toxin receptor in the IKCa1 external vestibule. First, we estimate the width of the IKCa1 toxin receptor to be ϳ31 Å (Fig. 5 ) based on the width of the IKCa1-binding surface of ShK (distance from Arg 1 to Phe 15 ). Second, the x-y dimension of the toxin receptor is estimated to be ϳ22 Å (Fig. 5, left) , based on the distance between the two toxin residues, ShK-Arg 11 and ShK-Arg 29 ( Fig.  5, right) , that interact with Asp 239 residues in adjacent IKCa1 subunits. This value implies (by Pythagorean triangulation) a distance of ϳ31 Å between Asp 239 residues in opposite subunits (Fig. 5) . We estimate that the toxin receptor is approximately ϳ8 -9 Å deep, based on the vertical distance between one horizontal line joining Arg 1 and Phe 15 , and a second horizontal line connecting the terminal amines of Arg 11 and Arg 29 ( Fig. 5,  right) . The selectivity filter is estimated to lie ϳ12-13 Å below the outer edge of the toxin receptor in the vestibule based on the vertical distance between the terminal amine of Lys 22 and the horizontal line joining Arg 1 and Phe 15 ( Fig. 5, right) . Our deduced dimensions of the toxin receptor in the IKCa1 vestibule are in good agreement with those obtained by crystallography for the KcsA vestibule (24, 25) , and by toxin-mapping for Kv1.3 (20, 21, 23) and Shaker (17) (18) (19) 22) .
Thus, the IKCa1 external vestibule appears to be topologically similar to those of the distantly related Kv1.3, Shaker, and KcsA channels, a result that provides support for the development of homology models of the IKCa1 outer pore based on the KcsA crystal structure. The experimentally determined differences in the ShK-IKCa1 and ShK-Kv1.3 binding interfaces raises the possibility of designing novel peptides and small molecule inhibitors that selectively target the IKCa1 channel. Such reagents might be useful in elucidating the role of the IKCa1 channel in diverse cell types and may also have therapeutic value.
